Silence Therapeutics plc (SLN) Tops Q1 EPS by 3c

Silence Therapeutics plc (NASDAQ: SLN) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $1.32 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.

You May Also Be Interested In

• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• Artelo files patent for ART27.13 in obesity, including GLP-1 combo
• General Mills (GIS) Tops Q1 EPS by 3c